View More Recent Stories
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
Cytokinetics (CYTK) Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
-
Cytokinetics (CYTK) Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
-
Cytokinetics (CYTK) PT Raised to $82 at RBC Capital Following Bayer Partnership
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
-
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces Initiation of Phase 1 Clinical Study of CK-4015089
-
Cytokinetics (CYTK) Misses Q3 EPS by 13c
-
Mizuho Reiterates Outperform Rating on Cytokinetics (CYTK)
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) PT Raised to $120 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces Data From Phase 1 Study of CK-4021586
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Cytokinetics (CYTK) PT Raised to $71 at JPMorgan
-
Mizuho Reiterates Outperform Rating on Cytokinetics (CYTK)
-
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) PT Raised to $92 at Jefferies
-
Goldman Sachs Downgrades Cytokinetics (CYTK) to Neutral
-
Eight defensive growth stocks to own right now
-
RBC's biotech survey shows investors more bearish vs. last time
-
Cytokinetics (CYTK) Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
-
Piper Sandler Reiterates Overweight Rating on Cytokinetics (CYTK)

